Worth The Extra Expense: PhRMA Makes Drug Cost-Effectiveness Case In New Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Group says new drugs’ higher costs greatly outweighed by decline in other healthcare spending, greater life expectancy.
You may also be interested in...
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
Merger will create the leading generic injectable pharmaceutical company in the world.
Sharer Replaces Dolan As PhRMA Chairman
Amgen CEO gets early promotion.